FABHALTA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FABHALTA (FABHALTA).
Fabhalta (iptacopan) is a complement factor B inhibitor that binds to factor B and prevents the formation of the alternative pathway C3 convertase, thereby inhibiting complement alternative pathway activation.
| Metabolism | Iptacopan is primarily metabolized by UGT1A1 and UGT1A3, with minor contributions from CYP3A4 and CYP2C8. |
| Excretion | Primarily renal (approximately 70% as unchanged drug) and biliary/fecal (approximately 30% as metabolites). |
| Half-life | Terminal elimination half-life is approximately 8 hours (range 6-10 hours), supporting twice-daily dosing for sustained complement inhibition. |
| Protein binding | Approximately 99% bound, primarily to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | Approximately 0.2 L/kg (about 14 L in a 70 kg adult), indicating limited extravascular distribution, consistent with confinement to the vascular space. |
| Bioavailability | Oral bioavailability is approximately 70% (range 60-80%) under fed conditions; food increases exposure by 20-30%. |
| Onset of Action | Oral: Clinical effect (reduction in hemolysis) observed within 1 week, with maximal effect by 4-6 weeks. |
| Duration of Action | Duration of action is approximately 12 hours, consistent with twice-daily dosing; pharmacodynamic effect (complement activity) returns to baseline within 24 hours of discontinuation. |
200 mg orally twice daily.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No dose adjustment required; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FABHALTA (FABHALTA).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or effects on milk production. Iptacopan is excreted in animal milk. M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, advise patients not to breastfeed during treatment and for 30 days after last dose. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. In animal reproduction studies, administration of iptacopan to pregnant mice during organogenesis resulted in embryofetal lethality and malformations at exposures below the human therapeutic exposure. Based on its mechanism of action (complement factor B inhibitor), there is a potential risk of complement-mediated clearance of immune complexes, which may affect fetal development. Risk cannot be excluded; avoid use in pregnancy unless clearly necessary. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concomitant use with complement inhibitors (e.g., eculizumab, ravulizumab) due to increased risk of thrombotic microangiopathy.","Hypersensitivity to iptacopan or any excipients."]
| Precautions | ["Increased risk of infections, including serious infections caused by encapsulated bacteria (e.g., Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae). Vaccination against these bacteria is required prior to therapy.","Potential for hemolysis due to complement activation; monitor for signs of hemolysis.","Interference with coagulation tests; Fabhalta may prolong prothrombin time and activated partial thromboplastin time due to inhibition of complement activation."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of infection, especially encapsulated bacterial infections (e.g., Streptococcus pneumoniae, Neisseria meningitidis) due to complement inhibition. Perform pregnancy test prior to initiation in females of reproductive potential. Monitor for thrombotic microangiopathy (TMA) and hemolytic uremic syndrome (HUS) if abrupt discontinuation. No specific fetal monitoring required beyond standard obstetrical care. |
| Fertility Effects | No human data on fertility. In animal studies, no adverse effects on male or female fertility at exposures up to 40 times the human exposure. However, based on mechanism, potential for impairment of complement-mediated clearance of apoptotic cells may theoretically affect reproductive processes. Consider fertility preservation counseling if planning pregnancy. |